Sage Theraputic RG (SAGE) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Sage Theraputic RG (SAGE)

An SI Board Since June 2018

Posts	SubjectMarks	Bans	Symbol
16	3	0	SAGE

Emcee: Lynn	Type: Moderated

Introduction Market Data Compact

Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical company focused on diseases affecting the central nervous system (CNS). Based in Boston, SAGE has a portfolio of drug candidates that modulate the gamma-aminobutyric acid (GABA) system. SAGE-547 is in development for and postpartum depression. Orally dosed SAGE-217 is in development for postpartum depression, major depressive disorder, essential tremor and Parkinson's disease.[copied from BoAML (ML)]

ML currently has a BUY on SAGE with a 12 month $200. price objective. Morgan Stanley has a $228. price target.

sagerx.com

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
16	FDA advisory committee back Sage's brexanolone for PPD Nov. 2, 2018 2:43	Lynn	-	11/4/2018
15	[Printed in IBD on 4 Sept.] This Biotech's Drug Had No 'Red Flags' I	Lynn	-	9/15/2018
14	Morgan Stanley (MS) should be releasing a new research report soon, as in if not	Lynn	-	9/12/2018
13	Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(	Lynn	-	8/4/2018
12	Sage Therapeutics Price Target Raised to $228.00/Share From $225.00 by Morgan St	Lynn	-	7/13/2018
11	3 Top Biotech Stocks to Buy for the 2nd Half of 2018 Keith Speights, The Motley	Lynn	-	7/11/2018
10	[June 25, 2018 at 17:58 PM EDT] A pharma CEO says a new depression drug could ha	Lynn	-	7/5/2018
9	Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration to	Julius Wong	-	6/14/2018
8	Analyst Actions: Canaccord Ups Sage Therapeutics Price Target to $220, Keeps at	Lynn	-	6/14/2018
7	Biotech Stock Loses Steam, But Analysts Still Bullish On Depression Drug ALLISON	Lynn	-	6/13/2018
6	Sage Therapeutics and Shionogi & Co., Ltd., Enter Strategic Collaboration	Lynn	-	6/13/2018
5	[12 June 2018] Why This Biotech Company Is Bounding Closer To A Breakout ALLI	Lynn	-	6/13/2018
4	Sage Announces Pivotal Phase 3 Trial Status for SAGE-217 in Major Depressive Di	Lynn	-	6/12/2018
3	Morgan Stanley [12 June 2018]: SAGE Therapeutics Inc - SAGE-217 PhIII Plan A Pos	Lynn	-	6/12/2018
2	Morgan Stanley Biotechnology [includes SAGE and a number of other companies, not	Lynn	-	6/4/2018
1	"Sage Therapeutics Announces FDA Acceptance Of NDA Filing And Grant Of Pri	Lynn	-	6/3/2018

Go to reply# or date (mm/dd/yy):